Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2024-09-10 Regulatory Filings
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports the entry into a material definitive agreement, specifically a promissory note issued by the company to its CEO. The document includes details about the loan and the promissory note, but it is not a full financial report, earnings release, or other comprehensive report. It is a regulatory filing to disclose a material event. The document length is 4024 characters, which is relatively short and typical for an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-10 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes a corporate update press release related to the second quarter ended June 30, 2024, following the filing of the company's Quarterly Report on Form 10-Q. The document itself is short (4270 characters) and primarily announces the press release and references the 10-Q filing but does not contain substantive financial data or the full quarterly report. According to the rules, such a document that announces or furnishes information without containing the full report or detailed financial data should be classified as a Regulatory Filing (RNS).
2024-09-04 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q2 2024
2024-09-04 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q1 2024
2024-09-04 English
Annual Report 2023
Annual Report FY 2023
2024-09-04 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically discusses the company regaining compliance with Nasdaq's minimum bid price requirement and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document is relatively short (4006 characters). This fits the profile of a Regulatory Filing (RNS) as it is an announcement of a regulatory event rather than a full financial report or other specific filing type.
2024-08-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.